← All trials
NCT05832489
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2023
- Primary completion
- Dec 30, 2026
- Completion date
- Dec 30, 2026
- First posted
- Apr 27, 2023
- Last posted
- Apr 27, 2023
- Enrollment
- 80
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of StrasbourgLead sponsor
- University of StrasbourgOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.